| Recruitment status | Enrolling by invitation |
| Unique ID issued by UMIN | UMIN000029815 |
| Receipt No. | R000031726 |
| Official scientific title of the study | The stiffness of liver and spleen, velocity of inferior vena cava, and skip perfusion pressure in patients with heart failure. |
| Date of disclosure of the study information | 2017/11/03 |
| Last modified on | 2018/02/28 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | The stiffness of liver and spleen, velocity of inferior vena cava, and skip perfusion pressure in patients with heart failure. | |
| Title of the study (Brief title) | Echo elastography, velocity of inferior vena cava, and skip perfusion pressure in patients with heart failure. | |
| Region |
|
|
| Condition | |||
| Condition | Heart Failure | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To assess the association between echo elastography, velocity of IVC, skin perfusion pressure and prognosis in patients with heart failure |
| Basic objectives2 | Others |
| Basic objectives -Others | Observational |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Cardiovascular death |
| Key secondary outcomes | Composite endpoint included all-cause death, cardiovascular death, and heart failure readmission and rates of each event. Serum BNP level. |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients who were admitted our hospital
Age greater than or equal to 20 years old Obtained written informed consent |
|||
| Key exclusion criteria | (1) patients with liver cirrhosis
(2) patients with dialysis (3) patients with acute coronary syndrome (4) patients with hematopoietic disorders (5) patients with portal hypertension (6) patients with acute viral infection (i.e. EB virus) (7) patients with splenomegaly due to infection (i.e. tuberculosis, malaria, and brucellosis) (8) patients with splenomegaly due to accumulation diseases (9) patients with splenomegaly due to autoimmune disorders (10) patients who can not be performed MRI (11) patients with arteriosclerosis obliterans in lower limb |
|||
| Target sample size | 100 | |||
| Research contact person | |
| Name of lead principal investigator | Toshitaka Okabe |
| Organization | Showa University Northern Yokohama Hospital |
| Division name | Division of Cardiology and Cardiac Catheterization Laboratories |
| Address | 35-1, Chigasaki-Chuo, Tsuzuki, Yokohama, Kanagawa, Japan |
| TEL | 045-949-7000 |
| sunyh-hf@hotmail.com | |
| Public contact | |
| Name of contact person | Toshitaka Okabe |
| Organization | Showa University Northern Yokohama Hospital |
| Division name | Division of Cardiology and Cardiac Catheterization Laboratories |
| Address | 35-1, Chigasaki-Chuo, Tsuzuki, Yokohama, Kanagawa, Japan |
| TEL | 045-949-7000 |
| Homepage URL | |
| sunyh-hf@hotmail.com | |
| Sponsor | |
| Institute | Showa University Northern Yokohama Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Enrolling by invitation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | Follow up patients to evaluate mortality, cardiovascular event and laboratory data.
By hospital visit or telephone contact. |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000031726 |